Yeh, Benjamin M., FitzGerald, Paul F., Edic, Peter M., Lambert, Jack W., Colborn, Robert E., Marino, Michael E., Evans, Paul M., Roberts, Jeannette C., Wang, Zhen J., Wong, Margaret J. and Bonitatibus, Peter J. (2017) Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies. Advanced Drug Delivery Reviews, 113 . pp. 201-222. DOI 10.1016/j.addr.2016.09.001.

Text Yeh.pdf - Reprinted Version Restricted to Registered users only Download (2MB)

Abstract

The introduction of spectral CT imaging in the form of fast clinical dual-energy CT enabled contrast material to be differentiated from other radiodense materials, improved lesion detection in contrast-enhanced scans, and changed the way that existing iodine and barium contrast materials are used in clinical practice. More profoundly, spectral CT can differentiate between individual contrast materials that have different reporter elements such that high-resolution CT imaging of multiple contrast agents can be obtained in a single pass of the CT scanner. These spectral CT capabilities would be even more impactful with the development of contrast materials designed to complement the existing clinical iodine- and barium-based agents. New biocompatible high-atomic number contrast materials with different biodistribution and X-ray attenuation properties than existing agents will expand the diagnostic power of spectral CT imaging without penalties in radiation dose or scan time.

Actions (login required)

View Item